Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope

Published on:

dna, genomics

Fresh off its first FDA approval, Apellis Pharmaceuticals is teaming up with Beam Therapeutics, a partnership that will use Beam’s base-editing technology to develop new therapies for complement system disorders. Apellis has committed to pay Beam $75 million to kick off the alliance.

Read more    Source: medcitynews.com